13721-39-6
13721-39-6 結構式
基本信息
原釩酸鈉
原釩酸鈉,十二水
正釩酸鈉
十二水合原釩酸鈉
十二水原釩酸鈉
原釩酸鈉 十二水
正釩酸鈉 十二水
正釩酸鈉
草酸鈉 SODIUM OXALATE
釩酸鈉
原釩酸鈉, 99.9% (METALS BASIS)
SODIUM ORTHOVANADATE
SODIUM ORTHOVANADATE(V)
SODIUM O-VANADATE
SODIUM VANADATE
SODIUM VANADATE, ORTHO
(beta-4)-vanadate(vo43-trisodium
Sodiumorthovanadate,dodecahyd
sodiumtetraoxovanadate(3-)
sodiumvanadate(v)(na3vo4)
sodiumvanadiumoxide(na3vo4)
trisodium(t-4)-vanadate(vo4(3-)
trisodium,(T-4)-Vanadate
trisodiumorthovanadate
trisodiumvanadate
vanadic(ii)acid,trisodiumsalt
Vanadicacidtrisodiumsalt
Sodium orthovanadate dodecahydrate
sodium tetraoxovanadate
trisodium tetraoxovanadate
物理化學性質
安全數(shù)據(jù)
常見問題列表
PPTPase.
In the presence of oxidizing agents vanadium ions exist as the hydrated monomer of Sodium orthovanadate (vanadate: HVO4 2- or H2VO 4- ) at micromolar concentations near neutral pH. Sodium orthovanadate (vanadate) also begins to polymerize at concentrations greater than 0.1 mM at neutral pH. The yellow-orange solutions of decavanadate can be converted to the colorless solutions of monomeric Sodium orthovanadate (vanadate) by dilution after a period of many hours. The process is hastened by boiling at pH 10, which encourages the kinetically sluggish depolymerization process. Sodium orthovanadate could alter the phosphorylation status of ASK1 at serine 83 and threonine 845 induced by ischemia. Sodium orthovanadate could increase the tyrosine posphorylation of PTEN and further inhibit the activation of ASK1 via activating Akt during cerebral ischemia.
知名試劑公司產(chǎn)品信息
Sodium orthovanadate, - 60 mesh, 99%(13721-39-6)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/03/03 | 081104 | 原釩酸鈉, 99.9% (metals basis) Sodium orthovanadate, 99.9% (metals basis) | 13721-39-6 | 500g | 11372元 |
| 2026/03/03 | 20533 | 原釩酸鈉(99%) Sodium orthovanadate, 99%, Thermo Scientific Chemicals | 13721-39-6 | 250g | 4361元 |
| 2025/12/22 | HY-D0852 | 釩酸鈉 Sodium orthovanadate | 13721-39-6 | 500mg | 400元 |